1. Home
  2. COCH vs BCAB Comparison

COCH vs BCAB Comparison

Compare COCH & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COCH
  • BCAB
  • Stock Information
  • Founded
  • COCH 1995
  • BCAB 2007
  • Country
  • COCH United States
  • BCAB United States
  • Employees
  • COCH N/A
  • BCAB N/A
  • Industry
  • COCH Blank Checks
  • BCAB Medicinal Chemicals and Botanical Products
  • Sector
  • COCH Finance
  • BCAB Health Care
  • Exchange
  • COCH Nasdaq
  • BCAB Nasdaq
  • Market Cap
  • COCH N/A
  • BCAB 27.0M
  • IPO Year
  • COCH N/A
  • BCAB 2020
  • Fundamental
  • Price
  • COCH $1.31
  • BCAB $0.35
  • Analyst Decision
  • COCH Strong Buy
  • BCAB Buy
  • Analyst Count
  • COCH 3
  • BCAB 2
  • Target Price
  • COCH $8.00
  • BCAB $1.00
  • AVG Volume (30 Days)
  • COCH 18.1K
  • BCAB 612.0K
  • Earning Date
  • COCH 03-31-2025
  • BCAB 03-27-2025
  • Dividend Yield
  • COCH N/A
  • BCAB N/A
  • EPS Growth
  • COCH N/A
  • BCAB N/A
  • EPS
  • COCH N/A
  • BCAB N/A
  • Revenue
  • COCH $225,000.00
  • BCAB $11,000,000.00
  • Revenue This Year
  • COCH $51.11
  • BCAB N/A
  • Revenue Next Year
  • COCH $92.00
  • BCAB N/A
  • P/E Ratio
  • COCH N/A
  • BCAB N/A
  • Revenue Growth
  • COCH N/A
  • BCAB N/A
  • 52 Week Low
  • COCH $1.21
  • BCAB $0.24
  • 52 Week High
  • COCH $7.20
  • BCAB $4.02
  • Technical
  • Relative Strength Index (RSI)
  • COCH 40.13
  • BCAB 44.62
  • Support Level
  • COCH $1.39
  • BCAB $0.28
  • Resistance Level
  • COCH $1.46
  • BCAB $0.40
  • Average True Range (ATR)
  • COCH 0.08
  • BCAB 0.04
  • MACD
  • COCH -0.01
  • BCAB 0.01
  • Stochastic Oscillator
  • COCH 15.38
  • BCAB 60.00

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Share on Social Networks: